Scher H I, Ahmed T, Yagoda A, Kyriazis A P, Watson R C
Cancer Invest. 1985;3(2):123-7. doi: 10.3109/07357908509017495.
A phase II trial with bisantrene was performed simultaneously against urothelial tumors in nude mice and in patients with metastatic transitional cell carcinoma. The starting dose was 260 mg/m2, intravenously, every 3 weeks. No responses were seen in the in vivo animal study or in 13 treated patients.
一项关于双胺苯吖啶的II期试验同时在裸鼠的尿路上皮肿瘤以及转移性移行细胞癌患者中开展。起始剂量为260mg/m²，静脉注射，每3周一次。在体内动物研究以及13例接受治疗的患者中均未观察到反应。
